ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
Current Medical Research and Opinion
◽
10.1080/03007995.2020.1799771
◽
2020
◽
Vol 36
(9)
◽
pp. 1507-1517
Author(s):
Arielle G. Bensimon
◽
Yichen Zhong
◽
Umang Swami
◽
Allison Briggs
◽
Joshua Young
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cost Effectiveness
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
First Line Treatment
Download Full-text
Related Documents
Cited By
References
Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma
Value in Health
◽
10.1111/j.1524-4733.2009.00617.x
◽
2010
◽
Vol 13
(1)
◽
pp. 61-68
◽
Cited By ~ 23
Author(s):
Martin Hoyle
◽
Colin Green
◽
Jo Thompson-Coon
◽
Zulian Liu
◽
Karen Welch
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cost Effectiveness
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
First Line Treatment
Download Full-text
A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
Clinical Genitourinary Cancer
◽
10.1016/j.clgc.2021.01.009
◽
2021
◽
Author(s):
Rebecca Shay
◽
Andrew Nicklawsky
◽
Dexiang Gao
◽
Elaine T. Lam
Keyword(s):
Renal Cell Carcinoma
◽
Cost Effectiveness
◽
Cell Carcinoma
◽
Renal Cell
◽
Cost Effectiveness Analysis
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
Effectiveness Analysis
◽
First Line Treatment
Download Full-text
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
JAMA Network Open
◽
10.1001/jamanetworkopen.2020.16144
◽
2020
◽
Vol 3
(10)
◽
pp. e2016144
Author(s):
Tina R. Watson
◽
Xin Gao
◽
Kerry L. Reynolds
◽
Chung Yin Kong
Keyword(s):
Renal Cell Carcinoma
◽
Cost Effectiveness
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
The Us
◽
First Line Treatment
Download Full-text
PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK
Value in Health
◽
10.1016/j.jval.2018.09.176
◽
2018
◽
Vol 21
◽
pp. S30
◽
Cited By ~ 1
Author(s):
E. Skentzou
◽
J. Meng
◽
J. Lister
◽
L. Gray
Keyword(s):
Renal Cell Carcinoma
◽
Cost Effectiveness
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
The Uk
◽
First Line Treatment
Download Full-text
PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE
Value in Health
◽
10.1016/j.jval.2019.09.410
◽
2019
◽
Vol 22
◽
pp. S477
Author(s):
S. Branchoux
◽
S. Négrier
◽
C. de Peretti
◽
B. Malcolm
◽
J. May
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cost Effectiveness
◽
Cell Carcinoma
◽
Renal Cell
◽
Cost Effectiveness Analysis
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
Effectiveness Analysis
◽
First Line Treatment
Download Full-text
PCN22 Cost-Effectiveness of Pembrolizumab PLUS Axitinib Versus Nivolumab PLUS Ipilimumab As First-LINE Treatment of Advanced Renal CELL Carcinoma
Value in Health Regional Issues
◽
10.1016/j.vhri.2020.07.072
◽
2020
◽
Vol 22
◽
pp. S8
Author(s):
T. Watson
◽
X. Gao
◽
K.L. Reynolds
◽
C.Y. Kong
Keyword(s):
Renal Cell Carcinoma
◽
Cost Effectiveness
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
First Line Treatment
Download Full-text
Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis
Annals of Oncology
◽
10.1093/annonc/mdz249.052
◽
2019
◽
Vol 30
◽
pp. v386-v387
Author(s):
M. Uemura
◽
Y. Tomita
◽
H. Miyake
◽
S. Hatakeyama
◽
H.-O. Kanayama
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Subgroup Analysis
◽
Renal Cell
◽
Phase Iii
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
Phase Iii Trial
◽
First Line Treatment
Download Full-text
First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis
Expert Opinion on Pharmacotherapy
◽
10.1517/14656566.2015.1058359
◽
2015
◽
Vol 16
(13)
◽
pp. 1915-1927
◽
Cited By ~ 15
Author(s):
James Larkin
◽
Abby Paine
◽
Grace Foley
◽
Stephen Mitchell
◽
Connie Chen
Keyword(s):
Systematic Review
◽
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Meta Analysis
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
First Line Treatment
Download Full-text
Correction to: “Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use”
Drugs & Therapy Perspectives
◽
10.1007/s40267-019-00613-z
◽
2019
◽
Vol 35
(4)
◽
pp. 200-200
Author(s):
Katherine A. Lyseng-Williamson
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
First Line Treatment
Download Full-text
Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
Drugs & Therapy Perspectives
◽
10.1007/s40267-018-0547-6
◽
2018
◽
Vol 34
(10)
◽
pp. 457-465
◽
Cited By ~ 4
Author(s):
Katherine A. Lyseng-Williamson
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Line Treatment
◽
First Line
◽
First Line Treatment
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close